Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression

Contributed by: PR Newswire

Tags

Oncoinvent-AS-Reports

More Like This

Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients

Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update

Oncoinvent ASA: Invitation to Result Presentation Q4 2024

Oncoinvent ASA announces oversubscribed private placement

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Oncorena receives FDA approval to initiate studies in the US

PR Newswire associated0

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

Business Wire logo

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer